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Globally, ovarian cancer is the fifih most common cancer among women that affects 
approximately 1 in 75 women in the developed countries. Over 75% of cases were 
presented at an advanced stage, with disease spread beyond the ovaries. To date, 
cervical cancer in women remains a major problem with about 400,000 new cases per 
year and almost 250, 000 reported deaths. However, this disease affects 
predominantly poor women in underdeveloped countries. It is estimated that 60% of 
the glcbal market for anticancer and anti-infectious drugs or those under clinical trial 
are of natural origin. Zerumbone, a sesquiterpene compound isolated from the 
rhizomes Zingiber zerumbet was shown to suppress TNF-a release and also induces 
apoptosis in a variety of human colonic adenocarcinoma cell lines. In this current 
study, the chemotherapeutic potential of zerumbone in cervical cancer (HeLa) and 
ovarian cancer (Caov-3) cell lines of human origin was evaluated together with 
cisplatin, a commercially used drug currently used for treating ovarian and cervical 
cancers. Exposure of both cancer cells to a range of zerumbone concentrations 
demonstrated growth inhibition in both cancer cells at a dose-dependent manner. The 
ICso values, determined by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,Sdiphenyl- 
tetrazolium bromide) reduction assay were as follows: zerumbone; Caov-3, 24.0 pM 
(5.2 pg/ml), HeLa, 20.7 pM (4.5 pg/ml) and cisplatin; Caov-3, 3.7 pM (1.1 pglml), 
HeLa, 5.3 pM (1.6 pg/ml). Laser scanning confocal microscopy following AOIPI 
staining were used to examine morphological changes of both cancer cells after 
zerumbone and cisplatin treatment. Apoptotic features that included membrane 
blebbing and nucleus condensation were evident in both treated cancer cells. 
Following this, TUNEL (TdT-mediated dUTP Nick-End Labeling) assay was 
conducted to confirm apoptosis. The studies conducted seems to suggest that 
zerumbone induce cell death by stimulating apoptosis better than cisplatin, based on 
significantly higher percentage of apoptotic cells in zerumbone treated cancer cells as 
compared to cisplatin. In addition, zerumbone and cisplatin arrests cancer cells at 
G2/M phase as analyzed by flow cytometry. Abnormal synthesis of 1L-6 appears to 
contribute to the pathogenesis of several kinds of diseases and the constitutive 
production of IL-6 has been implicated in malignant diseases. Increased levels of IL-6 
indicated the aggressiveness of a disease. IL-6 is suggested to provide prognostic 
value based on its role as a cancer cell growth factor. The effects of zerumbone on IL- 
6 levels were studied using a human base ELISA. The results indicated that 
zerumbone significantly decreased the levels of IL-6 secreted by both cancer cells. 
However, membrane-bound IL-6 receptor is still intact after zerumbone treatment as 
demonstrated using immunofluorescence technique. This study concludes that the 
compound, zerumbone inhibits both cancer cells growth through the induction of 
apoptosis, arrests cell cycle at G2/M phase and inhibits the secretion levels of IL-6 in 
both cancer cells. Therefore, zerumbone is a potential candidate as a useful 
chemotherapeutic agent in treating both cervical and ovarian cancers in future. 
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Secara global, kanser ovari ialah kanser yang kelima biasa berlaku di kalangan wanita 
dan dialami oleh 1 daripada 75 wanita di negara maju. Lebih daripada 75% kes 
adalah di peringkat akhir di mana kanser telah merebak ke semua bahagian ovari. 
Kanser serviks pada wanita merupakan masalah besar dengan 400, 000 kes baru 
dilaporkan setiap tahun dan menyebabkan 250, 000 kematian, tetapi dialami oleh 
lebih ramai wanita miskin di negara kurang membangun. Dijangkakan lebih kurang 
60% drug antikanser dan anti-jangkitan baik yang sudah berada di pasaran mahupun 
percubaan klinikal berasal dari alam semulajadi. Zerumbone, sebatian seskuiterpen 
yang diasingkan daripada rizom Zingiber zerumbet telah menunjukkan perencatan 
pengeluaran TNF-a dan merangsang apoptosis pada sel-sel selanjar adenokarsinoma 
kolon manusia. Di dalam kajian ini, dengan menggunakan sel selanjar kanser serviks 
(HeLa) dan kanser ovari (Caov-3) manusia, potensi kemoterapeutik zerumbone untuk 
kanser ovari dan serviks dikaji bersama cisplatin, drug antikanser komersil yang 
sekarang digunakan untuk kanser ovari dan serviks. Pendedahan sel-sel kepada julat 
kepekatan zerumbone yang berbeza menghasilkan perencatan pertumbuhan bagi 
kedua jenis sel kanser dengan bergantung kepada nilai kepekatan. Nilai lCso yang 
didapati daripada asai penurunan MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl- 
tetrazolium bromide) adalah seperti berikut: zerumbone; Caov-3, 24.0 pM (5.2 
pglml), HeLa, 20.7 pM (4.5 pglml) and cisplatin; Caov-3, 3.7 pM ( I .  1 pglml), HeLa, 
5.3 pM (1.6 pglml). Kajian morfologi menggunakan mikroskop fasa terbalik dan 
mikroskop imbasan laser konfokal selepas perwarnaan dengan AOIPI dijalankan 
untuk melihat perubahan morfologi bagi kedua sel kanser selepas rawatan zerumbone 
dan cisplatin. Ciri-ciri apoptosis seperti gelembung membran dan kondensasi nukleus 
telah didapati bagi kedua-dua sel selanjar yang dirawat. Seterusnya, asai TUNEL 
(TdT-mediated dUTP Nick-End Labeling) dijalankan untuk menentukan apoptosis. 
Menariknya, zerumbone didapati menyebabkan kematian sel dengan merangsang 
apoptosis lebih baik daripada cisplatin berdasarkan peratusan sel-sel apoptotik yang 
menunjukkan perbezaan yang signitikan berbanding sel-sel kanser dengan rawatan 
zerumbone. Tambahan pula, zerumbone dan cisplatin menahan sel-sel kanser di fasa 
G2/M seperti yang dianalisis dengan menggunakan 'flow cytometry'. Sintesis IL-6 
yang luar biasa dikatakan menyumbang kepada patogenesis beberapa penyakit dan 
penghasilan berterusan IL-6 telah diimplikasikan dalam penyakit malignan. 
Peningkatan tahap IL-6 menunjukkan perebakan penyakit secara agresif. IL-6 
dicadangkan mempunyai nilai prognostik berdasarkan fungsinya sebagai faktor 
pertumbuhan sel kanser. Kesan zerumbone terhadap tahap IL-6 dikaji menggunakan 
ELISA. Keputusan yang didapati menunjukkan zerumbone menurunkan tahap IL-6 
yang dirembes oleh kedua jenis sel kanser dengan signifikan. Walaubagaimanapun, 
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reseptor IL-6 yang terdapat di membran masih ada selepas rawatan zerumbone seperti 
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yang telah didemonstraskan melalui teknik immunofluoresen. Daipada kajian ini, 
didapati zerumbone merencat pertumbuhan sel-sel kanser dengan merangsang 
apoptosis, menahan pada fasa G2/M dan merencat tahap IL-6 sel HeLa dan sel Caov- 
3. Oleh itu, zerumbone dicadangkan mempunyai potensi perubatan untuk terapi 
kanser serviks dan ovari. 
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